Since overexpression of SLC7A11 and SLC3A2 also reduced sensitivity of ER+ breast cancer cells to Fulvestrant treatment (Fig. 5H), we hypothesized that drug targeting SLC7A11 and SLC3A2 should have efficacy against endocrine-resistant breast tumors by inducing ferroptosis. The gene discussed is SLC7A11; the disease is breast neoplasm.